20 September 2020: Lab/In Vitro Research
The Clinical Role of Preoperative Serum CA19-9 and Carcinoembryonic Antigen (CEA) Levels in Evaluating the Resectability of Advanced Gallbladder Cancer
Wencong Ma BCF* , Wei Li DE* , Jinghan Wang DF* , Rui Wu BC , Chen Liu D , Feiling Feng AF* , Xiaoqing Jiang AEF*DOI: 10.12659/MSM.925017
Med Sci Monit 2020; 26:e925017
Table 2 Relationships of preoperative CEA, CA19-9, and adjusted CA19-9 concentrations with resectability, total bilirubin concentration and AJCC staging.
| Variable | No. | CEA | CA19-9 | Adjusted CA19-9 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | Mean±SD | P value | Median | Mean±SD | P value | Median | Mean±SD | P value | ||
| Resectability | ||||||||||
| R0 | 169 | 2.8 | 11.55±33.29 | 0.000 | 41 | 175.18±294.60 | 0.000 | 26.97 | 43.93±58.34 | 0.000 |
| R1/R2 | 121 | 5.0 | 27.17±71.24 | 264.2 | 417.81±402.80 | 78.90 | 115.11±156.76 | |||
| Unresected | 19 | 5.3 | 57.51±95.76 | 149 | 412.73±436.10 | 97.50 | 158.53±219.00 | |||
| Total bilirubin | ||||||||||
| ≤23 μmol/L | 165 | 2.5 | 17.85±59.44 | 0.000 | 30 | 72.51±159.39 | 0.000 | 30 | 72.51±159.39 | 0.000 |
| >23 μmol/L | 144 | 5.1 | 23.52±54.41 | 403.1 | 528.04±390.75 | 68.16 | 86.12±69.41 | |||
| AJCC staging | ||||||||||
| II | 25 | 1.9 | 2.56±1.87 | 0.000 | 17 | 53.21±117.68 | 0.000 | 17 | 25.10±25.91 | 0.000 |
| IIIA | 60 | 2.75 | 8.17±24.49 | 46.3 | 195.10±321.34 | 27.40 | 42.72±42.55 | |||
| IIIB | 56 | 4 | 13.63±29.87 | 71.5 | 264.86±361.82 | 41.68 | 57.38±80.93 | |||
| IVA | 70 | 4.2 | 17.39±44.19 | 120.35 | 288.79±345.74 | 53.49 | 76.01±66.50 | |||
| IVB | 98 | 5.1 | 38.75±88.92 | 159.50 | 407.32±415.73 | 77.26 | 128.98±194.19 | |||
| AJCC – American Joint Committee on Cancer; SD – standard deviation; CA19-9 – carbohydrate antigen 19-9; CEA – carcinoembryonic antigen. | ||||||||||